WO2018174369A1 - Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant - Google Patents

Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant Download PDF

Info

Publication number
WO2018174369A1
WO2018174369A1 PCT/KR2017/013582 KR2017013582W WO2018174369A1 WO 2018174369 A1 WO2018174369 A1 WO 2018174369A1 KR 2017013582 W KR2017013582 W KR 2017013582W WO 2018174369 A1 WO2018174369 A1 WO 2018174369A1
Authority
WO
WIPO (PCT)
Prior art keywords
colostrum
lactic acid
acid bacteria
fermented
lactobacillus
Prior art date
Application number
PCT/KR2017/013582
Other languages
English (en)
Korean (ko)
Inventor
송혁
곽태일
김준혁
Original Assignee
주식회사 팜스킨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 팜스킨 filed Critical 주식회사 팜스킨
Publication of WO2018174369A1 publication Critical patent/WO2018174369A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986—Milk; Derivatives thereof, e.g. butter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

  • the present invention relates to a fermented product of colostrum and a cosmetic composition using the same, and more particularly, a fermentation product obtained by fermenting colostrum with a specific lactic acid bacterium and a functional composition obtained by using a new composition having an anti-inflammatory and skin irritant effect. It relates to a cosmetic composition.
  • the skin consists of the epidermis and the dermis.
  • the epidermis is constantly dividing cells, forming a variety of layers.
  • the outermost cells die and become hard, which is one of the best defenses to protect the body from external stress, and bacteria can't penetrate the skin.
  • the skin has sebaceous glands and sweat glands, the sebaceous glands secrete sebum, and the glands secrete water to create sebum membranes and protect the stratum corneum. Therefore, human skin is always moist, glossy and smooth. It becomes possible.
  • Cosmetics are intended to protect the skin from the outside, remodeling, and cleanliness, but when you look closely at the composition of the cosmetics, the ingredients that are necessary for the formation of the product, contrary to the original meaning, may be irritating to the skin. have. Examples include emulsifiers, fragrances and preservatives. They are most often made by chemical reaction synthesis, which increases the chances of inflammatory reactions, allergies and erythema in sensitive skin.
  • Lactic acid bacteria refers to bacteria that break down carbohydrates into lactic acid by metabolism. If the lactic acid is increased, the acidity is lowered, and the acidity occurs when the lactic acid bacteria themselves die. Therefore, fermentation time is important, and it is also a method to be resistant to oxidative stress.
  • Lactic acid produced by lactic acid bacteria plays a very large role. Antioxidant, anticancer, anti-radioactivity detoxification role and also has anti-inflammatory effect. It also has the ability to increase the water binding of the stratum corneum, which can improve fine wrinkles and soften the skin.
  • Interleukin-1 is a type of cytokine that is produced by several cells, such as activated monocytes, epithelial cells or vascular endothelial cells, and mediates inflammatory responses.
  • Another representative inflammatory component is the cytokine Tumor Necrosis Factor- ⁇ (TNF- ⁇ ).
  • Interleukin-10 inhibits the expression of enzymes related to inflammation, such as inducible nitric oxide synthase (iNOS) and inducible cyclooxyganase (COX-2), which are present in macrophages (Niiro, Hiroaki, et al, 1995). )
  • iNOS inducible nitric oxide synthase
  • COX-2 inducible cyclooxyganase
  • Lactoferrin is well known to play a role in the regulation of Tumor Necrosis Factor- ⁇ (TNF- ⁇ ) or Interleukin-1 (IL-1) (Yamanaka, 2003).
  • TNF- ⁇ Tumor Necrosis Factor- ⁇
  • IL-1 Interleukin-1
  • Colostrum also contains Insulin-like Growth Factor-1 (IGF-1), which is known to promote overall growth and have the ability to regulate cell growth and amplification (Uruakpa et al. , 2002).
  • IGF-1 Insulin-like Growth Factor-1
  • Casein which is contained in colostrum, accounts for 3% of the whole milk and about 80% of milk proteins, and it has been found to cause allergic effects on the body when ingested (G. H. Docena et al, 1996). Casein is also used as a cosmetic ingredient, but studies have not been fully conducted.
  • colostrum contains exfoliating ingredients (Kwon, Yu et al. 2007), and it is also known to contain TGF-beta, which inhibits melanin pigment and causes whitening effect (Martinez-Esparza M, et al. , 1997), and colostrum contains a lot of hyaluronic acid, which has been proven to have an excellent moisturizing effect (Pedersen, et al, 2014).
  • Korean Patent No. 10-0964831 proposes a cosmetic composition for promoting keratin differentiation containing colostrum as an active ingredient, wherein colostrum is used for anti-inflammatory, anti-allergic, and moisturizing effects.
  • This article describes the various usefulness of cosmetic application including the efficacy of promoting keratin differentiation of colostrum ingredients.
  • Korean Patent No. 10-1003740 discloses a novel Streptococcus thermophilus strain and fermented colostrum probiotic for swine using the same to improve the weight gain of livestock and to proliferate harmful microorganisms such as Escherichia coli and Salmonella. It is proposed to reduce the use of antibiotics and to improve productivity by preventing bacterial diarrhea disease and inhibiting the death of livestock.
  • Korean Patent Publication No. 10-2002-0021908 is a health supplement food that fermented colostrum using lactic acid bacteria, by reducing the content of harmful microorganisms present in colostrum by fermentation method using lactic acid bacteria, various functional substances possessed by colostrum. A health supplement that can be used as is is proposed.
  • Korean Patent No. 10-0619289 discloses a method for preparing a whitening cosmetics in which colostrum of colostrum is linked to arbutin, a whitening agent, and Korean Patent Publication No. 10-2009-0071998 discloses a skin keratin having colostrum as an active ingredient.
  • a composition for promoting differentiation has been proposed, and US Patent No. 5750149 proposes a technology relating to cosmetics containing substances derived from colostrum of horses.
  • Patent Document 1 Korean Registered Patent No. 10-0964831
  • Patent Document 2 Korean Registered Patent No. 10-1003740
  • Patent Document 3 Korean Patent Publication No. 10-2002-0021908
  • Patent Document 4 Korean Registered Patent No. 10-0619289
  • Patent Document 5 Korean Patent Publication No. 10-2009-0071998
  • Patent Document 6 US Patent No. 5,750,149
  • the present invention solves the problems of the prior art as described above, based on the results of the study of the availability of colostrum component, to prepare a high-functional fermentation product by fermenting colostrum component with lactic acid bacteria as a natural component.
  • an object of the present invention is to provide a colostrum fermentation product of a new composition in which colostrum is fermented with lactic acid bacteria.
  • Another object of the present invention to provide a use of colostrum lactic acid bacteria fermentation products as anti-inflammatory and skin irritation cosmetics.
  • Another object of the present invention to provide a method for producing a colostrum fermentation product of a new composition by fermenting colostrum component with lactic acid bacteria.
  • the present invention is colostrum Lactobacillus vulgaris ( Lactobacillus delbrueckii subsp . bulgaricus ) and Lactobacillus rhamnosus GG ), lactic acid bacteria, or Lactobacillus bacteria ( Lactobacillus ) and Streptococcus ( Streptococcus ) to provide a fermentation product of colostrum containing fermented lactic acid bacteria, including a composite lactic acid bacteria mixed ( Streptococcus ).
  • the present invention provides a cosmetic composition for anti-inflammatory and skin irritation relief comprising a specific colostrum lactic acid bacteria fermentation product.
  • the present invention is the step of quenching colostrum and then pasteurized to prepare a fermentation raw material; It provides a method for producing a colostrum lactic acid bacteria fermentation product comprising the step of inoculating and fermenting lactic acid bacteria to the fermentation raw material obtained in the step.
  • the present invention further comprises the step of obtaining a fermentation extract using the fermentation product enzyme; It provides a method for producing a colostrum lactic acid bacteria fermentation product comprising a.
  • Fermentation products by lactic acid bacteria fermentation of colostrum according to the present invention by using the lactic acid bacteria as a natural component to increase the specific active ingredients contained in colostrum and further improve the extraction efficiency by the active ingredient excellent compared to similar ingredients such as colostrum or milk It is contained.
  • the lactic acid bacteria fermented product of colostrum according to the present invention is simple and easy to manufacture, and because it is made of natural microorganisms conventionally used in food production, it is highly safe.
  • the colostrum fermentation product obtained by the lactic acid bacteria fermentation is very excellent anti-inflammatory effect compared to the existing shows an increased anti-inflammatory effect and skin irritation relief effect.
  • FIG. 1 is a process diagram illustrating an example of a process for preparing lactic acid bacteria fermented colostrum extract of colostrum according to an embodiment of the present invention, which is applied in an embodiment.
  • Figure 2 is an experimental example of the lactic acid bacteria fermented product of colostrum according to the present invention, a graph showing the experimental results for the anti-inflammatory effect of the lactic acid bacteria fermented colostrum extract prepared in Example.
  • FIG. 3 is an experimental example of the lactic acid bacteria fermented product of colostrum according to the present invention, it is a graph showing the experimental results for the skin irritation relaxation effect of the lactic acid bacteria fermented colostrum extract prepared in Example.
  • Figure 4 is an experimental example for the lactic acid bacteria fermented product of colostrum according to the present invention, a graph showing the experimental results for the antioxidant effect of the lactic acid bacteria fermented colostrum extract prepared in Example.
  • Figure 5 is an experimental example of the lactic acid bacteria fermented product of colostrum according to the present invention, a graph showing the experimental results for the cytotoxicity of the lactic acid bacteria fermented colostrum extract prepared in Example.
  • the present invention relates to a fermentation product of colostrum of a new composition obtained by fermentation with a specific lactic acid bacteria as a fermentation product having excellent utility obtained from colostrum.
  • Fermentation products obtained by the lactic acid bacteria fermentation of colostrum obtained in the present invention is excellent in anti-inflammatory activity, in order to replace and supplement the conventional chemical synthetic cosmetic composition, when applied to the production of natural cosmetic composition through lactic acid bacteria fermentation effect and skin irritation relief It can be provided as a new cosmetic composition with enhanced effect.
  • the present invention starts from the use of colostrum as a fermentation raw material to increase its utility.
  • the colostrum Lactobacillus vulgaris Lactobacillus Lactobacillus ( Lactobacillus ) Lactobacillus delbrueckii subsp . bulgaricus ) or Lactobacillus rhamnosus It provides a fermented product of colostrum lactic acid bacteria fermented with lactic acid bacteria, including GG ).
  • colostrum provides a fermented product of colostrum, fermented with lactic acid bacteria, including lactic acid bacteria mixed Lactobacillus ( Lactobacillus ) and Streptococcus ( Streptococcus ) mixed.
  • colostrum Lactobacillus delbrueckii subsp . bulgaricus provides a colostrum lactobacillus fermentation product, fermented with a lactic acid bacteria including a complex lactic acid bacteria mixed with at least one lactic acid bacteria selected from Streptococcus , more preferably Streptococcus thermophilus Can be.
  • Colostrum used as a fermentation raw material in the present invention can be preferably used salty milk within three days after delivery.
  • colostrum used as a fermentation raw material may preferably use bovine colostrum, where colostrum is a concept including colostrum of domestic animals such as goats and goats, but is not limited thereto.
  • the colostrum in order to use colostrum, for example, is rapidly cooled and then pasteurized to prepare a fermentation raw material.
  • Pasteurization treatment in the present invention can be carried out by a conventional pasteurization method.
  • the fermentation material obtained in the above step is inoculated with lactic acid bacteria and fermented to obtain a fermentation broth.
  • lactobacillus fermentation is Lactobacillus vulgaris ( Lactobacillus delbrueckii) subsp . bulgaricus ), Lactobacillus rhamnosus GG ) It is preferable to use one or more lactic acid bacteria selected from the group or complex lactic acid bacteria in which Streptococcus thermophilus is mixed. The selective use of such specific lactic acid bacteria can be an important factor in achieving the desired purpose.
  • Lactobacillus Bulgaria kusu (Lactobacillus delbrueckii subsp. Bulgaricus) are D- lactic acid from the fermentation process (D-Lactic acid) by a production represents a detoxification role and anti-inflammatory effects, effects to improve the anti-wrinkle and skin texture Can be expressed.
  • Lactobacillus rhamnosus GG is epithelialization material given to help eczema prevention, eczema can exhibit an effect in the prevention and Gram-positive bacteria is Staphylococcus aureus (staphylococcus aureus), or impede the growth perched on dead skin cells, keratinocyte migration and cell reproduction ( can contribute to re-epithelialization).
  • Lactobacillus Lactobacillus
  • Streptococcus thermophilus may have a desirable effect on the skin, such as the formation of the stratum corneum layer structure or increase the amount of ceramide necessary for this function.
  • Lactobacillus rhamnosus GG and Streptococcus thermophilus ( Streptococcus thermophilus ) to produce interleukin-10 as a synergistic effect by using the mixture, excellent anti-inflammatory Can be effective.
  • lactic acid bacteria when using the lactic acid bacteria as described above, due to the use of these lactic acid bacteria will exhibit a synergistic effect to enhance the anti-inflammatory effect with lactoferrin of colostrum.
  • Lactobacillus delbrueckii used as lactic acid bacteria Lactobacillus delbrueckii subsp . bulgaricus
  • Streptococcus thermophilus can provide a more favorable synergistic effect for mixed use in that both bacteria provide polyamines to protect themselves from oxidative stress.
  • a composite lactic acid bacteria mixed Lactobacillus ( Lactobacillus ) and Streptococcus ( Streptococcus ) is preferably induce the production of lactic acid and antibacterial, anti-inflammatory effect As it improves the synergistic effect can be expected.
  • Lactobacillus Bulgaria kusu Lactobacillus delbrueckii subsp. Bulgaricus
  • Lactobacillus ramno suspension support Lactobacillus rhamnosus GG
  • Streptococcus thermophilus Streptococcus thermophilus
  • the fermentation of lactic acid bacteria can be inoculated with the above lactic acid bacteria in pasteurized colostrum which is a fermentation raw material and can be fermented for 30 to 120 minutes at a temperature of 30 ⁇ 50 °C.
  • the fermentation product of colostrum after undergoing the lactic acid bacteria fermentation process, can be obtained through centrifugation to obtain a fermentation broth.
  • the lactic acid bacterium fermentation product of the present invention may be one in which casein is removed.
  • the lactic acid bacteria fermentation product of colostrum may preferably include additionally obtaining the fermentation extract using the fermentation broth enzyme.
  • the step of obtaining the fermentation extract by using the fermentation broth is preferably, for example, undergoing an agglomeration process to purify the colostrum fermentation broth after the lactic acid bacteria fermentation.
  • the fermentation broth may include a step of obtaining lactic acid bacteria fermented colostrum extract by aggregating using an enzyme.
  • the functional component content can be increased by removing those that may have a negative effect such as casein contained in the fermentation broth obtained by the lactic acid bacteria fermentation, or by removing the high-casein in milk protein. Therefore, the enzyme is added to remove the casein and other components through the aggregation reaction.
  • the enzyme may further comprise a purification process comprising the step of centrifuging and filtering the enzyme additive.
  • a purification process comprising the step of centrifuging and filtering the enzyme additive.
  • an enzyme complex for the role of a coagulant may be used, and specifically, for example, rennet may be preferably used.
  • Rennet illustrated herein refers to an enzyme complex in the stomach of a ruminant animal.
  • rennet is a coagulase containing rennin, one of the proteolytic enzymes, and it is known to be contained in the calf's gastric juice with pepsin. It is known that it has a characteristic of precipitating, and cheese that is aged shortly using bovine gastrointestinal enzyme rennet has a good aroma and a smooth mouth feel.
  • Enzymes used in the present invention can be understood to include all enzymes exhibiting properties similar to the aforementioned rennet.
  • an enzyme represented by such a rennet when used, it can be preferably used to cause the aggregation of casein contained in lactic acid bacteria fermented colostrum to remove casein.
  • the fermentation broth of colostrum obtained after the lactic acid bacteria fermentation may be aggregated for 30 to 120 minutes after the enzyme is added at 30 to 40 ° C.
  • the enzyme addition process may be further subjected to the aggregation process for the components such as casein and then centrifuged and filtered to recover the fermentation broth.
  • the lactic acid bacteria fermented product of colostrum which is substantially free of casein components, can be obtained.
  • the lactic acid bacteria fermented product of colostrum thus obtained may be prepared in the form of lactic acid bacteria fermented colostrum extract from which casein has been removed.
  • the lactic acid bacteria fermentation product of colostrum may be prepared by further filtering and sterilizing.
  • the lactic acid bacteria fermented colostrum extract obtained according to the present invention may be used by removing bacteria that may be present after filtration twice or several times.
  • Lactic acid bacteria fermented colostrum extract obtained through the above steps according to the present invention is an example of the lactic acid bacteria fermented product of colostrum, it was confirmed that exhibits a very useful property different from any components previously derived from colostrum.
  • the lactic acid bacteria fermented product of colostrum according to the present invention includes any one or more of fermentation broth obtained by fermenting colostrum into specific lactic acid bacteria, fermentation broth substantially free of casein, sterilized fermentation broth, and lactic acid bacteria fermented colostrum extract purified from fermentation broth. can do.
  • An example of the most preferred type of fermentation product of colostrum according to the present invention may be purified lactic acid bacteria fermented colostrum extract that is sterilized without casein by purifying the fermentation broth.
  • the colostrum by treating the colostrum with a specific lactic acid bacteria as described above, it can exhibit an excellent effect unlike the prior art, in particular, since the combined use of the lactic acid bacteria of the present invention exhibits a synergistic effect, It was confirmed that it shows the outstandingly excellent activity compared with the use of lactic acid bacteria.
  • the lactic acid bacteria fermented product of colostrum according to the present invention in particular, lactic acid bacteria fermented colostrum extract obtains the effect on useful effects such as inhibition of cytokine generation and anti-inflammatory activity by lactic acid bacteria fermentation, and when purified by casein, etc.
  • lactic acid bacteria fermented colostrum extract obtains the effect on useful effects such as inhibition of cytokine generation and anti-inflammatory activity by lactic acid bacteria fermentation, and when purified by casein, etc.
  • the present invention in order to replace and supplement the chemical synthetic cosmetic composition is a cosmetic that is used in the past, by producing a natural cosmetic composition using the lactic acid bacteria fermentation products of acetic acid according to the present invention to reduce the skin inflammation and skin irritation effect The provision of enhanced new cosmetic compositions.
  • the skin in the case of the cosmetic composition containing the colostrum fermentation product of colostrum of the present invention, the skin is very significant by inhibiting the occurrence of pro-inflammatory satokine and promoting the expression of Interleukin-10. It can exhibit anti-inflammatory and skin stimulating effects.
  • the lactic acid bacteria fermentation product of colostrum in the cosmetic composition may be contained in an amount of 0.01 to 40% by weight based on the total weight of the composition. Outside the lower limit of the above content range, the effect is remarkably reduced. Outside the upper limit, it is difficult to prepare a cosmetic formulation, or it is not preferable in terms of economics.
  • the lactic acid bacteria fermented product of colostrum prepared by the method as described above may be added to the cosmetic composition, for example, as a lactic acid bacteria fermented colostrum extract, for example, powdery, liquid, nanocapsules, complex It may be added in the form of, and the like, and may be added in a liquid phase as a preferred example.
  • a lactic acid bacteria fermented colostrum extract for example, powdery, liquid, nanocapsules, complex It may be added in the form of, and the like, and may be added in a liquid phase as a preferred example.
  • a cosmetic composition containing lactic acid bacteria fermentation product of colostrum can be used in cosmetic formulations such as lotion (skin lotion), nutrition lotion, nutrition cream, massage cream, nutrition essence, cleanser, mask pack, and the like. It is not limited, and may be used in other hair preparations or skin preparations for various functional effects.
  • the lactic acid bacteria fermented product of colostrum contained in the cosmetic composition prepared according to the present invention is the raw material used in the manufacturing process is colostrum and the lactic acid bacteria used to ferment it is a natural microorganism that has conventionally been used in food production, and thus stability of the extract itself.
  • the excellent anti-inflammatory and skin irritation-relieving effect expressed synergistically through the lactic acid bacteria fermentation it is possible to prevent the occurrence of inflammation in advance, as well as remarkably excellent dermatitis when using cosmetics containing these ingredients in the skin It is expected to be very useful as a new concept cosmetic composition because it can exhibit a relaxing effect and skin irritation relaxing effect.
  • Fermented colostrum extract was prepared by the same process as in the process of FIG.
  • Step 1 prepare raw materials
  • Second step production of lactic acid bacteria fermentation broth
  • Lactobacillus delbrueckii subsp . bulgaricus , ATCC 11842), Streptococcus thermophilus ( ATCC 19258), Lactobacillus rhamnosus GG , ATCC 53103) three kinds of complex bacteria were inoculated into the fermentation raw material of the first step and fermented at a temperature of 35 °C 60 minutes to obtain a fermentation product (fermentation liquid).
  • Step 3 Preparation of Lactic Acid Bacteria Fermented Colostrum Extract
  • the fermentation broth obtained in the second step is centrifuged at 2000 rpm for 20 minutes to remove the suspended matter, and the supernatant except the precipitate is recovered to obtain the fermented colostrum as a fermentation product of colostrum.
  • the fermented colostrum is adjusted to 33 ° C., and agnetted for 60 minutes by adding Rennet to recover the fermented colostrum.
  • the fermented colostrum obtained above was centrifuged at 13000 rpm for 60 minutes to obtain a supernatant as a fermented colostrum extract that is a lactic acid bacteria fermentation product.
  • Example 1 the lactic acid bacteria fermentation products were prepared in the same manner as in Example 1 by adjusting the microorganisms or complex bacteria inoculated into the fermentation raw material of the first step.
  • Example 2 Lactobacillus delbrueckii subsp . bulgaricus , ATCC 11842) Example 3 Lactobacillus rhamnosus GG, ATCC 53103 Example 4 Lactobacillus delbrueckii subsp . bulgaricus , ATCC 11842) + Lactobacillus rhamnosus GG, ATCC 53103 Example 5 Lactobacillus delbrueckii subsp . bulgaricus , ATCC 11842) + Streptococcus thermophilus ( ATCC 19258) Example 6 Lactobacillus rhamnosus GG ( ATCC 53103) + Streptococcus thermophilus ( ATCC 19258)
  • the fermentation product of colostrum was prepared in the same manner as in Example 1, using Streptococcus thermophilus ( ATCC 19258) alone as a bacterium used for fermentation.
  • Lactobacillus Bulgaria kusu same as in the method of Example 2, except that Figure the Lactobacillus ash instead of (Lactobacillus delbrueckii subsp. Bulgaricus, ATCC 11842) using the filler's (Lactobacillus acidophilus, ATCC 4356) It carried out by the method, the lactic acid bacteria fermented colostrum extract was prepared.
  • Lactobacillus Bulgaria kusu Lactobacillus delbrueckii subsp. Bulgaricus, ATCC 11842
  • Streptococcus Thermo filler's Streptococcus thermophilus, ATCC 19258
  • Lactobacillus fermented colostrum extract was prepared in the same manner as in Example 6 except for using Streptococcus thermophilus ( ATCC 19258).
  • LPS Lipopolysaccharide
  • Activated macrophages are TNF ⁇ , an inflammation-inducing cytokine. Increases the expression level of IL-1 ⁇ , IL-12, IFN ⁇ and the like.
  • Inflammatory cytokines produce Nitric oxide (NO). Therefore, the anti-inflammatory effect was evaluated by reducing the amount of NO expression.
  • RAW 264.7 cells were suspended in DMEM (Dubelccos Modified Eagle Medium, Gibco) animal cell culture medium containing 10% FBS, and 5 X 10 5 was added to each well of a 24 well plate at 37 ° C and 5% CO 2. Incubate for one day at. Thereafter, the medium was washed twice, group A was LPS, group B was LPS + unfermented colostrum extract, group C was LPS + Streptococcus thermophilus ( ATCC 19258) fermented colostrum extract , group D was LPS + Fermented colostrum extract (Example 1) was put together and further incubated for 18 hours.
  • DMEM Dubelccos Modified Eagle Medium, Gibco
  • the grease reagent was added to the cell supernatant for quantification of NO and reacted for 15 minutes, and the absorbance was measured at 540 nm with an ELISA reader. Sodium nitrite was used as a standard solution.
  • the fermented colostrum extract As shown in Table 2 and Figure 2, it can be confirmed that the fermented colostrum extract, a colostrum fermentation product according to the embodiment, has a superior NO inhibitory effect by LPS treatment as compared to the unfermented colostrum extract.
  • a patch test was performed on the forearm of 20 adult men and women (10 males and 10 females) in their 20s. Skin irritation was used 0.1% by weight of sodium lauryl sulfate (SLS), group A fermented SLS only, group B fermented SLS + non-fermented colostrum extract, group C fermented SLS + Streptococcus thermophilus ( ATCC 19258) Colostrum extract, D group was applied to the skin for 1 day as SLS + fermented colostrum extract (Example 1). After the patch was finished, the test site was marked with a pen, and after 24 hours, the skin reaction of the test site was determined according to the criteria of Table 3 below.
  • SLS sodium lauryl sulfate
  • group A fermented SLS only group B fermented SLS + non-fermented colostrum extract
  • group C fermented SLS + Streptococcus thermophilus ATCC 19258 Colostrum extract
  • D group was applied to the skin for 1 day as S
  • Free radical Free radical for fermented colostrum extract according to the embodiment under the same conditions as unfermented colostrum extract , Streptococcus thermophilus ( ATCC 19258) fermented colostrum extract through DPPH ( ⁇ -diphenyl- ⁇ -picrylhydrazyl) method Radical) scavenging effect was measured.
  • Experimental methods include group A (unfermented colostrum extract), group B Streptococcus thermophilus ( ATCC 19258) fermented colostrum extract, and group C (fermented colostrum extract) in 0.2 ml of DPPH dissolved in ethanol in 96 well plates. Each 0.2 ml of Example 1) was dispensed, and then reacted at room temperature for 30 minutes. Thereafter, absorption adsorption was measured at 525 nm. The control group added ethanol instead of the sample.
  • DPPH radical scavenging ability was calculated by the method of the following formula (2).
  • DPPH radical scavenging activity (%) (absorbance of 1-extract additive / absorbance of control) X 100
  • the fermented colostrum extract of the fermentation product of colostrum according to the embodiment is superior to the free lyric scavenging effect than the unfermented colostrum extract.
  • the EZ-cytox Cell Viability Assay method is a method for measuring cell viability by using the dehydrogenase of mitochondria of living cells, and evaluated the toxicity of fermented colostrum extract according to the example.
  • RAW 264.7 cells were used as a cell line, and DMEM (Dubelccos Modified Eagle Medium, Gibco) containing 10% FBS and 100UL S / P was used as an animal cell culture medium.
  • 24 well plate 5x10 5 cells were added to each well and incubated for 24 hours at 37 °C, 5% CO 2 incubator. Thereafter, 12 wells were added to the culture medium plate without addition of the extract (control), and the remaining 12 were fermented colostrum extract (Example experimental group) and further cultured for 24 hours.
  • EZ-cytox solution was added to all wells and reacted for 1 hour and measured at 450 nm with a plate reader.
  • the fermented colostrum extract of the fermentation product of colostrum according to the embodiment can be confirmed that there is no cytotoxicity.
  • LPS Lipopolysaccharide
  • Activated macrophages are TNF- ⁇ , an inflammation-inducing cytokine. Increase the expression levels of IL-1 ⁇ , IL-12, IFN ⁇ and the like. Inflammatory cytokines produce Nitric oxide (NO). Therefore, the anti-inflammatory effect was evaluated by reducing the amount of NO expression.
  • RAW 264.7 cells were suspended in DMEM (Dubelccos Modified Eagle Medium, Gibco) animal cell culture medium containing 10% FBS, and 5 X 10 5 was added to each well of a 24 well plate at 37 ° C and 5% CO 2. Incubate for one day at. Thereafter, the medium was washed twice and the sample was prepared, and then the LPS was mixed with the prepared sample at a concentration of 1 ⁇ g / ml and treated at the same time in a cell at 37 ° C. in a 5% CO 2 incubator for 18 hours.
  • DMEM Dubelccos Modified Eagle Medium, Gibco
  • the skin response of the test site was also determined according to the above criteria.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne : un produit de colostrum fermenté par des bactéries lactiques ; une composition cosmétique le contenant à titre de principe actif ; et son procédé de préparation. Un produit de colostrum fermenté par des bactéries lactiques, ayant une stabilité élevée obtenue par fermentation du colostrum par des microorganismes naturels généralement utilisés pour la production d'aliments, et ayant des effets anti-inflammatoires et des effets d'atténuation d'irritation de la peau particulièrement améliorés obtenus par ladite fermentation avec des bactéries lactiques spécifiques est en outre décrit. Le produit de colostrum fermenté par des bactéries lactiques obtenu dans la présente invention peut être utilisé dans une composition cosmétique anti-inflammatoire et pour atténuer l'irritation de la peau.
PCT/KR2017/013582 2017-03-24 2017-11-27 Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant WO2018174369A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0037930 2017-03-24
KR20170037930 2017-03-24

Publications (1)

Publication Number Publication Date
WO2018174369A1 true WO2018174369A1 (fr) 2018-09-27

Family

ID=63584518

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2017/013582 WO2018174369A1 (fr) 2017-03-24 2017-11-27 Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant
PCT/KR2018/003492 WO2018174669A1 (fr) 2017-03-24 2018-03-23 Produit fermenté de colostrum et composition cosmétique l'utilisant

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003492 WO2018174669A1 (fr) 2017-03-24 2018-03-23 Produit fermenté de colostrum et composition cosmétique l'utilisant

Country Status (2)

Country Link
KR (1) KR20180108504A (fr)
WO (2) WO2018174369A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110075004A (zh) * 2019-06-05 2019-08-02 惠州学院 一种复合生物酶医用修复面膜及其制备方法
CN113952284A (zh) * 2020-02-26 2022-01-21 广州留今科学研究有限公司 一种共生菌组合发酵物及其制备方法和应用
CN116121088A (zh) * 2022-08-12 2023-05-16 华熙生物科技股份有限公司 一种酿酒酵母菌及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102311097B1 (ko) * 2017-12-29 2021-10-08 주식회사 팜스킨 초유의 호기성 발효산물
KR102248535B1 (ko) * 2019-09-17 2021-05-06 주식회사 팜스킨 초유 유래 항산화 조성물
US20210275612A1 (en) * 2020-03-09 2021-09-09 Glac Biotech Co., Ltd. Method for alleviating inflammation-related disorder
KR102366276B1 (ko) * 2020-03-12 2022-02-23 주식회사 팜스킨 미세먼지에 의한 세포독성으로부터 피부를 보호하기 위한 피부보호용 조성물
CN112370390B (zh) * 2020-11-27 2022-06-28 奥克斯路株式会社 一种抗衰老、去皱、修护肌肤屏障的发酵液及其制备方法
CN112940968B (zh) * 2021-02-07 2022-07-01 山东凤凰生物科技股份有限公司 一种发酵乳杆菌、发酵乳杆菌的培养物及其制备方法
CN114262675A (zh) * 2021-12-20 2022-04-01 无锡弘焕微生态科技有限公司 复合菌发酵滤液的制备及其美白功效在化妆品中的应用
CN114081901B (zh) * 2021-12-23 2023-08-29 山东锦鲤生物工程有限公司 一种益生菌组合物、制备方法及其应用
KR20240082753A (ko) 2022-12-02 2024-06-11 주식회사 팜스킨 초유 가수분해물을 함유하는 피부장벽 강화 및 보습용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08214888A (ja) * 1995-02-16 1996-08-27 Iwakoshi Takeshi 発酵時の温度制御に特徴のあるグルジア乳酸品−１の 製造法
US20050095317A1 (en) * 2002-02-15 2005-05-05 Compagnie Gervais Danone Novel method for the production of fermented milk products
WO2009007655A1 (fr) * 2007-07-03 2009-01-15 Danisco A/S Procede de fabrication de lait fermente pour l'alimentation d'animaux nourris au lait
KR20120041494A (ko) * 2010-10-21 2012-05-02 순천대학교 산학협력단 유청과 초유를 이용한 액상 발효사료 및 이의 제조방법
JP2016164144A (ja) * 2010-05-21 2016-09-08 株式会社明治 皮膚状態の改善用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100964831B1 (ko) * 2007-12-28 2010-06-24 충남대학교산학협력단 초유를 함유하는 피부외용제 조성물
JP6579605B2 (ja) * 2015-05-20 2019-09-25 再生ファーマ株式会社 皮膚改善剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08214888A (ja) * 1995-02-16 1996-08-27 Iwakoshi Takeshi 発酵時の温度制御に特徴のあるグルジア乳酸品−１の 製造法
US20050095317A1 (en) * 2002-02-15 2005-05-05 Compagnie Gervais Danone Novel method for the production of fermented milk products
WO2009007655A1 (fr) * 2007-07-03 2009-01-15 Danisco A/S Procede de fabrication de lait fermente pour l'alimentation d'animaux nourris au lait
JP2016164144A (ja) * 2010-05-21 2016-09-08 株式会社明治 皮膚状態の改善用組成物
KR20120041494A (ko) * 2010-10-21 2012-05-02 순천대학교 산학협력단 유청과 초유를 이용한 액상 발효사료 및 이의 제조방법

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110075004A (zh) * 2019-06-05 2019-08-02 惠州学院 一种复合生物酶医用修复面膜及其制备方法
CN113952284A (zh) * 2020-02-26 2022-01-21 广州留今科学研究有限公司 一种共生菌组合发酵物及其制备方法和应用
CN113952284B (zh) * 2020-02-26 2023-08-01 广州留今科学研究有限公司 一种共生菌组合发酵物及其制备方法和应用
CN116121088A (zh) * 2022-08-12 2023-05-16 华熙生物科技股份有限公司 一种酿酒酵母菌及其应用

Also Published As

Publication number Publication date
KR20180108504A (ko) 2018-10-04
WO2018174669A1 (fr) 2018-09-27

Similar Documents

Publication Publication Date Title
WO2018174369A1 (fr) Produit de colostrum fermenté par des bactéries lactiques et composition cosmétique l'utilisant
WO2011010770A1 (fr) Nouvelle souche de lactobacillus plantarum et composition la contenant
WO2010064777A1 (fr) Nouveau lactobacillus plantarum et composition le contenant
WO2014193014A1 (fr) Bactéries lactiques de taille nanométrique issues du kimchi
WO2020040407A1 (fr) Nouvelle souche de cutibacterium avidum, et composition pour prévenir ou traiter la dermatite atopique, comprenant une souche ou un produit cultivé associé
WO2022086041A1 (fr) Nouvelle souche de lactobacillus sp. et son utilisation
WO2018030732A1 (fr) Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation
WO2014069874A1 (fr) Composition permettant d'éliminer des substances kératiniques de la peau comprenant des lactobacillus de thé vert
WO2018056600A1 (fr) Composition topique pour apaiser la peau, contenant comme principe actif un extrait de germe de blé fermenté
WO2018084528A1 (fr) Composition antioxydante et d'amélioration de la peau
WO2021162415A1 (fr) Composition cosmétique pour l'amélioration de la peau comprenant, en tant que principes actifs, des polysaccharides, un extrait de levure et un produit de fermentation de souche ayant des caractéristiques de probiotiques
WO2017164681A1 (fr) Composition cosmétique destinée à soulager la dermatite atopique, contenant, en tant que principes actifs, une solution de culture de lactobacillus rhamnosus, ou une solution de culture de lactobacillus rhamnosus et de l'acide linoléique conjugué
WO2010064778A1 (fr) Nouveau lactobacillus plantarum et composition le contenant
KR102311097B1 (ko) 초유의 호기성 발효산물
WO2019088421A1 (fr) Composition pour le traitement de lésions de cellules cutanées provoquées par les poussières fines, contenant des bactéries lactiques dérivées du thé vert
AU2021212021B2 (en) Pharmaceutical composition for preventing or treating atopic disease containing Akkermansia muciniphila strain
KR102615147B1 (ko) 초유 발효산물의 항여드름용 화장료
WO2019059668A2 (fr) Composition pour la peau contenant, en tant que principe actif, de la crème de lait liquide fermentée par des bactéries lactiques
WO2020111674A1 (fr) Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine
WO2020101414A1 (fr) Composition favorisant la régénération cutanée et la poussée capillaire, contenant de l'apigénine
WO2019172554A1 (fr) Composition cosmétique de blanchiment de la peau contenant une solution de mélange de cultures de lactobacilles
CN116077415A (zh) 一种用于调节皮肤微生态平衡的三元益生因子组合物
CN116350529A (zh) 用于改善或维持哺乳动物皮肤健康的方法和组合物
KR101541843B1 (ko) 발효 밤송이 추출물을 유효성분으로 함유하는 피부 주름 방지 및 항균 조성물
TW202220681A (zh) 皮膚細菌叢改善劑及皮膚細菌叢改善用皮膚外用劑

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17901418

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17901418

Country of ref document: EP

Kind code of ref document: A1